OmniGuide pulls in $35M to market laser surgery tech

Cambridge, MA's OmniGuide has snagged $35 million in financing from OrbiMed, planning to expand adoption of its BeamPath CO2 laser system for minimally-invasive surgeries.

OmniGuide says the investment will give it flexibility for years to come as it moves toward profitability. The BeamPath system combines cutting, ablation and coagulation, while doing minimal thermal damage to nearby tissues, OmniGuide says. The company has launched versions designed for surgeries in the brain; head and neck; ear, nose and throat (ENT); and other tissues.

The cash infusion will help OmniGuide get its tech into the hands of more surgeons, CEO Scott Flora said, and the company is honored to work with OrbiMed, the world's largest healthcare-dedicated investment firm. 

"We are excited to have a high-quality investor with substantial experience in healthcare make a major funding commitment to our company," Flora said in a statement. "We look forward to benefiting from the collective experience the OrbiMed team will bring to OmniGuide."

OmniGuide's devices are based on technology developed at MIT, and the company designs and manufactures the BeamPath system in-house at its Cambridge headquarters. Since its launch, the system has been used in more than 40,000 adult and pediatric procedures in gynecology, ENT and neurosurgery, the company says.

- check out OmniGuide's release

Like what you're reading?
Click here to get more news delivered to your inbox everyday >>

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.